Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q86SZ2
UPID:
TPC6B_HUMAN
Alternative names:
-
Alternative UPACC:
Q86SZ2; B3KPS2; Q5JPD6; Q86U35; Q86X35
Background:
Trafficking protein particle complex subunit 6B plays a crucial role in inter-organelle traffic, particularly influencing neural circuitry development. It controls intracellular calcium transients, essential for neuron differentiation and survival.
Therapeutic significance:
Linked to a neurodevelopmental disorder characterized by microcephaly, epilepsy, and brain atrophy, understanding Trafficking protein particle complex subunit 6B's role could unveil new therapeutic strategies.